Quality CareFind out why Mayo Clinic is the right place for your health care. Make an appointment.
Meet the StaffFind a directory of doctors and departments at all Mayo Clinic campuses. Visit now.
Research and Clinical TrialsSee how Mayo Clinic research and clinical trials advance the science of medicine and improve patient care. Explore now.
Visit Our SchoolsEducators at Mayo Clinic train tomorrow’s leaders to deliver compassionate, high-value, safe patient care. Choose a degree.
Professional ServicesExplore Mayo Clinic’s many resources and see jobs available for medical professionals. Get updates.
Give to Mayo ClinicHelp set a new world standard in care for people everywhere. Give now.
Mayo Clinic offers appointments in Arizona, Florida and Minnesota and at Mayo Clinic Health System locations.
Subscribe to Housecall
Our general interest e-newsletter keeps you up to date on a wide variety of health topics.
Mayo Clinic is studying a new way of treating colorectal cancers that have spread to the liver.
TheraSphere is a targeted way of delivering radiation through tiny glass beads containing radioactive yttrium-90.
The radioactive glass beads are only about 20-30 micrometers in diameter — about a third of the width of a human hair — and are delivered directly into the liver tumors.
TheraSphere uses radioactive microspheres that emit radiation over a period of several weeks. TheraSphere treatment is also referred to as radioembolization or selective internal radiation therapy.
TheraSphere is delivered into the hepatic artery of the liver through a catheter. The tiny radioactive beads flow directly to the liver tumor via the blood where they lodge into the small blood vessels of the tumor. The radiation destroys the tumor cells from within the tumor with minimal impact to the surrounding healthy tissue of the liver.
A new study is open at Mayo Clinic Cancer Center and others around the country using TheraSphere to treat people who have a diagnosis of colorectal cancer that has spread to the liver.
For this study, people who have disease progression with oxaliplatin or irinotecan based first line chemotherapy and are eligible for treatment will receive second-line standard-of-care chemotherapy with either an oxaliplatin-based or an irinotecan-based chemotherapy regimen. The patient's primary tumor (the colorectal cancer) must be unresectable and stable.
Those with previous radiation therapy to the liver aren't eligible. Neither are people who have cancer that has spread to other parts of the body. Additional inclusion and exclusion criteria apply.
For more information, please call the Mayo Clinic Clinical Trials Referral Office at (855) 776-0015. If you'd like to see if this trial is offered in your area, you can search for clinical trial NCT01483027 on clinicaltrials.gov.
Sheryl M. Ness, R.N.
Selecting "Submit" signifies that you have read and agree to our posting guidelines.
Is there any information on use of TheraSphere in patients with liver metasteses from breast cancer?
i recieved thera spheres at roswell park cancer center,bufalo,n.y. Went home same day,easy tresions have shrunk. teatment. My last visit i was told my disease is stabilized! L
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.
We comply with the HONcode standard for trustworthy health information: verify here.